

Message from Chairman

First of all, I would like to send my sincerest condolences to the families and friends of those who passed away due to COVID-19. At the same time, I hope patients will recover as soon as possible and express my gratitude to the medical professionals engaged in their treatment. In addition, I would like to express my heartfelt sympathy to the residents of the areas affected by the heavy rainfall in July.

JKMA developed "The Future Vision for Kampo Medicines 2040" in July 2018. The elderly population is expected to peak in 2040 in Japan. Therefore, this is a long-term vision for 20 years to contribute to public wellness and healthcare through the supply of Kampo products and crude drug products, for instance, prolonging healthy life expectancy. In this fiscal year, JKMA completed an interim report on the Medium-to-Long-Term Business Plan established as a five-year plan, starting from 2017. To achieve "The Future Vision for Kampo Medicines 2040," JKMA will create a medium-to-long-term road map and a five-year action plan, and will review the organization for further effectiveness.

The COVID-19 outbreak can affect procurement of crude drugs and other ingredients imported from China and other countries. However, we are currently procuring raw materials without issue. In FY2020, we will continue to contribute to people's health and healthcare by steadily securing crude drugs for Kampo preparations, stably supplying high-quality Kampo products and others based on crude drugs, securing the safety of Kampo products and others based on crude drugs, and promoting the proper use.

It is very important to exchange opinions and share the latest information such as on the quality, safety and necessary quantity of crude drugs with China, the greatest provider of crude drugs for Kampo preparations, in order to secure crude drugs for Kampo preparations stably. JKMA has continued to mix periodically with China Chamber of Commerce for Import & Export of Medicines & Health Products directly controlled by the Ministry of Commerce to establish a good relationship.

Domestically, we regard the expansion of the production of crude drugs as an important challenge, supporting the promotion of medicinal crop farming in some areas as a project aided by the Ministry of Agriculture, Forestry and Fisheries through The Medicinal Crop Production Region Support Council. JKMA conducted a medicinal crop growing area survey in the previous fiscal year. It found that the cultivation area increased approximately 20% from about 410 ha in FY2012 to about 490 ha in FY2017, when the growing area was compared before and after our involvement. We will continue to conduct the growing area survey as an indicator of our activities this fiscal year. Additionally, JKMA will clarify the items for stable production to promote an increase in medicinal crop cultivation in Japan.

On the other hand, several challenges will still take time, such as the systematization of medicinal crop producers, the rise in efficiency from the introduction of machines, and the training of cultivation technicians. We require assistance from municipal governments as well as the Ministry of Agriculture, Forestry and Fisheries to solve these issues. Your continued understanding and cooperation are appreciated.

The authorities are currently discussing the revision of the GMP Ministerial Ordinance, which will require us to introduce a pharmaceutical quality system. JKMA will aid corporate members in making improvements and assure quality more appropriately, for example, holding workshops about the introduction, the construction and the operation of a pharmaceutical quality system for corporate members in cooperation with PMDA, so that all corporate members can comply with and operate the GMP Ministerial Ordinance more appropriately.

The 18th Edition of the Pharmacopoeia of Japan is expected to include 37 formulations of Kampo extracts, planned to be enforced in 2021. Recognizing that Kampo products are positioned as important pharmaceuticals in insurance-backed healthcare, we will continuously make concerted efforts to assure quality in the process from crude drugs for Kampo preparations to final products to produce and provide preparations with high homogeneity.

The FY2020 drug price reform permitted an increase in prices of three Kampo products for ethical use and five crude drug ingredients to elevate too low prices of drugs without substitutes.

It was the first application of this type of price rise for Kampo products for ethical use. Additionally, the classification was continued for the 62 crude drug ingredients that were classified as basic drugs in the FY2018 NHI price revision. It is important to stabilize drug prices for the stable supply of Kampo products and others based on crude drugs for ethical use. To stably provide Japanese people with Kampo products and others based on crude drugs for ethical use in preparation for the next drug price system revision, we will appeal to the authorities to advocate and continue to include Kampo products in basic drugs.

For OTC Kampo and crude drug products, the self-medication promotion task force of The Federation of Pharmaceutical Manufacturers' Association of Japan and general pharmaceutical manufacturers' associations are discussing requests for amendments, for instance, extending or making permanent the self-medication tax system that was originally planned to continue for five years from 2017, and allowing all OTC drugs, including OTC Kampo and crude drug products, to be used for Rx-to-OTC switch.

JKMA will support these actions for the tax system amendment.

The Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices was amended and published last December. The following will be implemented successively: A system for observing laws and regulations will be arranged, a penalty system will be developed against sales of pharmaceuticals and others using false/dazzling advertising, package inserts will be computerized, and pharmaceutical products and others will be required to have bar codes. We checked the compliance of corporate members and revised the JKMA Behavior Charter and the JKMA Compliance Program Guideline to respond to environmental changes, such as enforcement of the act on clinical research and publication of guidelines for Whistle-blower Protection Act. We will familiarize corporate members with these matters, arrange a system, and promote compliance with the guidelines for the provision of sales information about pharmaceuticals for ethical use.

We appreciate your continued guidance and support.

Terukazu Kato, Japan Kampo Medicines Manufacturers Association

JKMA Outline

Established

Japan Kampo Medicines Manufacturers Association (JKMA) was established on July 21, 1983 by domestic manufacturers and distributors (including importers) of Kampo products and crude drug products derived from crude drug, as well as other businesses associated with raw materials for crude drug.

Aims

Based on close cooperation among its members, JKMA provides continuous and stable supply of high-quality Kampo formulation, crude drug formulation, and crude drug. By enhancing its roles and functions, JKMA aims to contribute to the growth of the pharmaceutical industry and the health of the nation by disseminating, embedding and developing Kampo formulation, crude drug formulation, and crude drug.

Present Situation

As an industrial body, JKMA is affiliated with the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ), an organization representing all pharmaceutical industries in Japan.

As of July 1, 2020, JKMA has 63 member companies.

Board of Directors



Chairman

Terukazu Kato



Vice-chairman

Hideki Yoshikawa



Vice-chairman

Masahiro Iwakura



Vice-chairman

Ippei Suzuki



Vice-chairman

Kazumasa Kobayashi



Vice-chairman

Shoichi Kuwano



Managing Director

Yoshio Machida

Chairman

Terukazu Kato
Tsumura & Co.

Vice-chairman

Hideki Yoshikawa
Uchida Wakanyaku Ltd.

Masahiro Iwakura
Kracie Pharmaceutical, Ltd.

Ippei Suzuki
Kotaro Pharmaceutical Co., Ltd.

Kazumasa Kobayashi
Kobayashi Pharmaceutical Co., Ltd.

Shoichi Kuwano
Nippon Funmatsu Yakuhin Co., Ltd.

Managing Director

Yoshio Machida
Japan Kampo Medicines Manufacturers Association

Director

Masaki Mizuno
Asgen Pharmaceutical Co., Ltd.

Osamu Ushimaru
Alps Pharmaceutical Ind. Co., Ltd.

Takashi Okusa
Ohkusa Yakuhin Co., Ltd.

Yoshiaki Ohta
Ohta's Isan Co., Ltd.

MasaoTsuji
Ominedo Pharmaceutical Industry Co., Ltd.

Takateru Sato
Kenso-Seiyaku Co., Ltd.

Kunio Takahashi
Zaiseido Pharmaceutical Co., Ltd.

Katsuyoshi Sakamoto
Sakamoto Kampo Pharmaceutical Inc.

Seiichi Sato
Sato Pharmaceutical Co., Ltd.

Koichi Watanabe
Sampo Pharmaceutical Co., Ltd.

Mitsuo Murayama
Sanwa Shoyaku Co., Ltd.

Seiji Kobayashi
JPS Pharmaceutical Co., Ltd.

Mitsuhiro Ibe
Zeria Pharmaceutical Co., Ltd.

Katsuhiko Yoshida
Daiichi Sankyo Healthcare Co., Ltd.

Takashi Shibata
Taiko Pharmaceutical Co., Ltd.

Akira Uehara
Taisho Pharmaceutical Co., Ltd.

Mari Nogami
Takeda Consumer Healthcare Company Limited

Yoshitake Tatebayashi
Tatebayashi Shokakudo Co., Ltd.

Daisuke Tochimoto
Tochimoto Tenkaido Co., Ltd.

Takehiko Asayama
Honso Pharmaceutical Co., Ltd.

Taro Shiozawa
Yomeishu Seizo Co., Ltd.

Ryuta Fujii
Ryukakusan Co., Ltd.

Kunio Yamada
Rohto Pharmaceutical Co., Ltd.

Masaki Wakiyashiki
Wakanyaku Medical Institute Ltd.

Kanji Wakunaga
Wakunaga Pharmaceutical Co., Ltd.

Auditor

Atsushi Hori
Kyushin Pharmaceutical Co., Ltd.

Takahiro Ueda
Teikoku Kampo Seiyaku Co., Ltd.

Senior Executive Advisor

Hachizaemon Kazama
Tsumura & Co.

Advisor

Yasuto Mitani
Kanebo Pharmaceutical Co., Ltd.

Hidetoshi Imaizumi
Daiichi Sankyo Healthcare Co., Ltd.

Masao Onishi
Kotaro Pharmaceutical Co., Ltd.

Yoichi Nakashima
Kracie Pharmaceutical, Ltd.

*Alphabetical order of company name.

*For Senior Executive Advisor and Advisors, the company name is shown at the time of their retirement.

The Future Vision for Kampo Medicines 2040

- Responsibility for People's Health and Healthcare -

In May 2018, the Japanese government released the prospect for future social security in 2040. The report predicts that Japan's elderly population will peak in 2040. To contribute to people's health and healthcare in an aging society, for instance, extending healthy life expectancy by supplying Kampo products and others based on crude drugs, we have established "The Future Vision for Kampo Medicines 2040 - Responsibility for People's Health and Healthcare -."

Vision 1 We will accumulate scientific evidence under industry-government-academia cooperation and enhance the usefulness of Kampo products and others based on crude drugs in medical care.

1. Accumulation of evidence

We will encourage the establishment of methods for evaluating usefulness, the scientific elucidation of shou that is the unique concept for Kampo, and medical economics research to contribute to the establishment of evidence-based medicine in Kampo treatment. In addition, we will contribute to the healthy lives of many patients by accumulating evidence of new uses, including supportive therapy in cancer treatment and medical care for frailty in the elderly.

2. Inclusion of Kampo products and others based on crude drugs for ethical use in these practice guidelines

We contribute to expanding the range of treatment by accumulating evidence to increase formulations listed on treatment guidelines to allow many physicians to use Kampo products and others based on crude drugs.

3. Securing of safety and promotion of proper use of Kampo products and others based on crude drugs

We at JKMA will independently prepare the materials for providing information about proper use of Kampo products and others based on crude drugs and will disseminate information to healthcare facilities and general users via our website and other media. We will continue to raise the value of Kampo products and others based on crude drugs as pharmaceutical products and will establish the usefulness in healthcare.

Vision 2 We will diligently try to procure the necessary quantity of crude drugs for Kampo preparations.

1. Securing of necessary quantity of crude drugs for Kampo preparations

As for domestic cultivation, we will increase production about three times by solving many issues, for instance, securing seeds and seedlings, training cultivation technicians and instructors, founding processing/preparation facilities, and raising efficiency and ensuring continuity of production. Today, we import approximately 80% of crude drugs for Kampo preparations from China. In this context, we will try to maintain a favorable relationship with the country. In addition, we will increase sources to manage the risk of delayed procurement caused by natural calamities and abnormal weather.

2. Promotion of cultivation of crude drugs for Kampo preparations

We will conduct a survey on the ratios of cultivated forms and wild forms of crude drugs to choose preferred items and promote cultivation without limiting production areas.

3. Japan-China interchange for stable procurement of crude drugs for Kampo preparations

We are currently communicating with China and exchanging information. We will regularly interchange with China to maintain and develop a successful bilateral relationship and stably secure crude drugs for Kampo preparations.

Vision 3 We will strengthen the quality control process from crude drugs for Kampo preparations to finished products for the stable supply of quality Kampo products and others based on crude drugs.

1. Assurance of quality of crude drugs for Kampo preparations

We will enhance surveillance and research on quality, including origin, properties, verification tests, and quantitative methods of crude drugs, and train the crude drug managers who play a key role in good manufacturing practices for Kampo to upgrade the level of quality control for crude drugs comprehensively.

2. Assurance of quality in the process from crude drugs for Kampo preparations to final products, and stable supply

We will ensure thorough quality control with good manufacturing practices and voluntary standards as well as the stable supply of quality Kampo products and others based on crude drugs. Additionally, we will advocate familiarization with the JKMA version of GACP among farmers and assure quality in the safety in crude drugs for Kampo preparations, Kampo products and others based on crude drugs, for instance, controlling pesticide residue, heavy metal, and microorganisms.

3. Response to ISO/TC 249

We will respond to ISO/TC 249 appropriately and use information on other ISO technical committees effectively by offering new suggestions and submitting opinions about the activities associated with the quality of crude drugs for Kampo preparations.

4. Stable supply of Kampo products for ethical use

To continuously secure a stable supply of Kampo products and others based on crude drugs for ethical use, we will approach administrative bodies and related organizations.

Vision 4

We will expand the development of new dosage forms and research on additional indications of Kampo products for ethical use and support the establishment of guidelines for applications of pharmaceuticals containing multiple ingredients, such as Kampo products.

1. Promotion of research on Kampo products and others based on crude drugs and the establishment of guidelines for applications for pharmaceuticals containing multiple ingredients

We will promote the development of new dosage forms and research on additional indications of Kampo products for ethical use. In addition, we will support the establishment of guidelines for applications for pharmaceuticals containing multiple ingredients.

Vision 5

We will boost the development of OTC Kampo products and crude drug products and enhance post-marketing information provision.

1. Encouragement of self-medication

We will encourage self-medication through the development and fulfillment of OTC Kampo products that are made from crude drugs and crude drug products.

2. Development of OTC Kampo products and crude drug products

The environment exists for approval of Kampo products and others based on crude drugs, for example, inclusion of more formulations in standards of approval. We will continue to advocate research and development of OTC Kampo products and crude drug products.

3. Enhancement of provision of information on OTC Kampo products and crude drug products

We will enhance outreach activities for consumers by sharing actual cases of consultations with consumers and providing information and materials via lecture meetings and leaflets.

4. Advertisements of OTC Kampo products and crude drug products

We will enhance the advertising functions in cooperation with the related organizations and promote the proper use of OTC Kampo products and crude drug products.

Vision 6

We will upgrade reliability by strengthening compliance as well as quality and safety control for Kampo products and others based on crude drugs in corporate members.

1. Fortification of compliance activities

We will promote the construction and rearrangement of the compliance system and elevation of corporate ethics, and prevent corporate scandals to increase trust among people.

2. Fortification of the three-key-role system

To facilitate the execution of jobs in the three key roles as defined in the laws and regulations, we will request that corporate members fortify the three-key-role system to upgrade reliability in quality and safety control for Kampo products and others based on crude drugs.

Vision 7

We will contribute to the conservation of the global environment and biological diversity, the protection of wild plants and animals, and will proactively work toward the international expansion of crude drugs that are natural blessings.

1. Enhancement of eco-friendly activities

We will contribute to the achievement of a low carbon society, a recycling-based society, and a natural symbiosis society in consideration of global trends including the Paris Agreement and SDGs.

2. Appropriate response to international treaties including the Convention on Biological Diversity

We will observe the domestic laws of the crude drug producing countries under the principles of the Convention on Biological Diversity and the Nagoya Protocol on Access and Benefit-sharing. We will observe the domestic laws relating to endangered species in accordance with CITES.

3. Promotion of international expansion of Kampo products and others based on crude drugs

We will transmit the knowledge of Kampo products and others based on crude drugs from Japan to the world to contribute to the improvement of global public health and promote the international expansion of these products.

Vision 8

We will implement outreach activities and enhance collaboration with the related organizations, academic societies, research institutions, administrative bodies, and others.

1. Provision of information to people and fulfillment of outreach activities

We will try to popularize Kampo by providing information to effectively raise awareness. Additionally, we will fulfill outreach activities to build trust through interactive dialogues with people.

2. Enhancement of collaboration with academic societies and universities relating to crude drugs and Kampo

We will enhance collaboration with academic societies and universities related to crude drugs and will cooperate in human resource development, for example, organizing symposiums at academic meetings concerning crude drugs in the industry and proactively sending lecturers to special lectures about Kampo and crude drugs at universities.

3. Enhancement of cooperation with the related organizations, academic societies, research institutions, administrative bodies, and others

We will enhance communications with the related organizations, academic societies, research institutions, administrative bodies, and others and solve issues under satisfactory cooperation promptly and properly.

Business Plan for Fiscal 2020

The production of Kampo products and others based on crude drugs reached 192.7 billion yen or the highest value ever while there was growth for both Kampo products and others based on crude drugs for ethical use and OTC Kampo products and others based on crude drugs. This is evidence of the contribution of Kampo products and others based on crude drugs on people's wellness and medical care.

In FY2020 again, we at JKMA will contribute to people's health and healthcare by steadily procuring crude drugs for Kampo preparations, stably supplying quality Kampo products and others based on crude drugs, ensuring safety, and promoting the proper use along with all members.

We will promote more activities to achieve "The Future Vision for Kampo Medicines 2040."

JKMA recently implemented activities to solve multiple issues.

JKMA established the 2017 Medium-to-Long-Term Business Plan (Five Year Plan) while incorporating six recommendations released by Forum: The Vision for Kampo Medicine and Public Welfare jointly set up with the Japan Society for Oriental Medicine. We made an interim report on the activity results in FY2019. In addition, we established "The Future Vision for Kampo Medicines 2040" (hereinafter, "New Vision") in 2018. It will contribute to people's health and healthcare, for example, by extending healthy life expectancy by supplying Kampo products and others based on crude drugs. (2040 refers to the prediction that the elderly population in Japan will peak that year.) The business plan for FY2020 will include the establishment of a mid- and long-term road map and a five-year action plan to achieve the vision in 20 years, continuing toward the New Vision. Moreover, we will review our organization to increase viability.

We will try hard to procure crude drugs for Kampo preparations steadily and to secure quality in the process from crude drugs to final products.

Today, we import about 80% of crude drugs for Kampo preparations from China. It is important to maintain a good relationship with the country through China-Japan interchange to procure the necessary quantity of high-quality crude drugs among rising domestic demand in China. Therefore, we will maintain close ties with China, for instance, by sharing the latest information and exchanging opinions with the China Chamber of Commerce for Import and Export of Medicines and Health Products.

Domestically, five deals regarding cultivated crops were concluded in the previous fiscal year, while we are advancing activities for supporting the cultivation of medicinal crops in multiple areas in the project aided by the Ministry of Agriculture, Forestry and Fisheries. This fiscal year, we will enhance support for cultivation technique guidance and consignment of quality testing in test growing, champion real cultivation, and clarify the items that need to be stably produced by farming to increase domestic production.

As for pesticide residue, we will summarize fact-finding survey results, assess the risk of pesticides outside voluntary standards, and discuss the revision of voluntary standards. In addition, we will investigate the real state of management of mycotoxin by a variety of companies and support the strengthening of management systems.

For International Organization for Standardization/Technical Committee 249 (ISO/TC 249), we will work on the international standardization of GACP based on the JKMA version of GACP through the joint China-Japan proposal.

This year, the amended ministerial ordinance on GMP based on PIC/S GMP will be enforced. Following the enforcement, we will advance understanding of corporate members and action for appropriate operation with respect to the PQS-related requirements to be incorporated in the ministerial ordinance, such as the workshop concerning introduction, construction and operation of PQS that was held last February.

We at JKMA will ensure the necessary quantity and quality of crude drugs for Kampo preparations and continue to try to secure the quality and stable supply of final products.

We will ensure adherence to the amended Pharmaceutical and Medical Device Act, and a more substantial and stronger compliance system for both JKMA and corporate members.

The amended Pharmaceutical and Medical Device Act was promulgated last December, which will lead to gradual implementation of a variety of measures. Systems for compliance will be arranged, such as for supervisory systems, and clarification of responsibilities as managers and persons in charge of sites. Additionally, a penalty system will be established to prevent false/excessive advertisements, package inserts will be computerized, and the indication of bar codes on pharmaceutical packages will become mandated. In FY2020, we will support familiarization and establishment of systems among corporate members.

Unfortunately, some cases of violation of the Pharmaceutical and Medical Device Act occurred in the previous fiscal year. Therefore, we will recheck compliance with the act for corporate members and familiarize them with the importance of compliance. Moreover, we will review the JKMA Behavior Charter and the JKMA Compliance Program Guideline, encourage understanding, and advocate compliance for all corporate members.


In addition, we will advance adherence to the guidelines for the provision of information on sales of pharmaceutical products for ethical use so that all corporate members can fulfill the responsibility as pharmaceutical companies.

Roles of industrial commissions, projects, and functional committees

Common matters

1. Matters relating to corporate ethics
2. Matters relating to cooperation with, negotiations with, and information collection from administrative bodies and related organizations
3. Matters relating to business plans and business reports
4. Matters relating to budget

Organization of JKMA



Ethical Kampo Products Commission

Ethical Kampo Products Commission consists of 12 member companies handling ethical Kampo formulation and its bulk extracts.



Chairman
Terukazu Kato,
Tsumura & Co.



Ethical Kampo Products Committee
Chairman
Hisashi Hasegawa,
Tsumura & Co.

1. Nurturing of Kampo products for ethical use and crude drug products
2. Matters relating to adherence to fair competition rules and disclosure of Transparency Guidelines
3. Matters relating to improvement of distribution
4. Matters relating to general training of medical representatives (MRs)
5. Matters relating to usefulness of Kampo products for ethical use, such as accumulation of evidence

Crude Drugs Commission

Crude Drugs Commission consists of 29 member companies handling raw materials for crude drug (captive consumption, sales), and companies handling crude drug for dispensing and other final products.



Chairman
Hideki Yoshikawa,
Uchida Wakanyaku Ltd.



Crude Drugs Committee
Chairman
Makoto Shiratori,
Uchida Wakanyaku Ltd.

1. Matters relating to quality of crude drugs
2. Matters relating to distribution of crude drugs, such as survey on actual distribution of crude drugs for Kampo preparations
3. Matters relating to cultivation of crude drugs inside and outside Japan
4. Matters relating to revision of Japanese Pharmacopoeia and non-JP crude drug standards in connection with crude drugs
5. Matters relating to safety of crude drugs in China, such as survey on use of pesticides
6. Matters relating to CITES

OTC Kampo Products Commission

OTC Kampo Products Commission consists of 38 member companies handling OTC Kampo formulation.



Chairman
Masahiro Iwakura,
Kracie Pharmaceutical, Ltd.



OTC Kampo Products Committee
Chairman
Yoshiaki Nagashima,
Kracie Pharmaceutical, Ltd.

1. Matters relating to provision of information on OTC Kampo products to consumers
2. Matters relating to standards for approving OTC Kampo product formulations
3. Matters relating to training activities for OTC Kampo products
4. Matters relating to promotion of proper use of OTC Kampo products
5. Matters relating to cooperation on information provision and survey/research on usefulness of OTC Kampo products

Crude Drug Products Commission

Crude Drug Products Commission consists of 27 member companies handling crude drug formulation.



Chairman
Kazumasa Kobayashi,
Kobayashi Pharmaceutical Co., Ltd.



Crude Drug Products Committee
Chairman
Atsunori Wada,
Kobayashi Pharmaceutical Co., Ltd.

1. Matters relating to promotion of development and quality assurance of crude drug products
2. Matters relating to information provision and promotion of proper use of crude drug products
3. Matters relating to cooperation with the groups and organizations associated with crude drug products

Bulk Extracts Commission

Bulk Extracts Commission consists of 5 member companies manufacturing all types of extracts such as tinctures, dry extracts and so on.



Chairman
Shoichi Kuwano,
Nippon Funmatsu Yakuhin Co., Ltd.



Bulk Extracts Committee
Chairman
Hiroshi Sasaki,
Nippon Funmatsu Yakuhin Co., Ltd.

1. Matters relating to inclusion of Kampo formulations and extracts in official compendiums
2. Matters relating to water used for manufacturing of crude drug extracts
3. Matters relating to quality of crude drug extracts
4. Matters relating to drug affairs, laws, and regulations concerning crude drug extracts

Future Vision Project for Kampo Medicines and Public Welfare



Project Leader
Kenji Ajioka,
Tsumura & Co.

1. Matters relating to cross-cutting/sustainable development of industrial commissions and functional committees in connection with Kampo products, crude drug products, and crude drugs
2. Matters relating to realization of recommendations by Forum: The Vision for Kampo Medicine and Public Welfare

General Affairs Committee



Chairman
Shingo Takeshita,
Tsumura & Co.

1. Matters relating to business policies, business plans, and business reports
2. Matters relating to management of budget, account settlement and others
3. Matters relating to efficient operation of JKMA activities
4. Matters relating to promotion of admission of new members
5. Matters relating to compliance
6. Matters relating to lecture meetings
7. Matters relating to production of Kampo products and others based on crude drugs
8. Matters relating to environmental practice
9. Cooperation with the related organizations

Public Relations Committee



Chairman
Ritsuko Inukai,
Tsumura & Co.

1. Matters relating to PR for JKMA activities
2. Matters relating to educational activities concerning Kampo products and crude drugs
3. Matters relating to handling of inquires and interviews by news organizations and the like
4. Matters relating to handling of inquires by general consumers, medical professionals and governments
5. Matters relating to maintenance and administration of websites

International Committee



Chairman
Takashi Morota,
Tsumura & Co.

1. Matters relating to international exchange concerning Kampo products and crude drugs
2. Matters relating to discussion on responses to changes in international situations and sharing of discussion results in connection with Kampo products and crude drugs
3. Matters relating to cooperation in the organizations associated with international issues concerning Kampo products and crude drugs

Pharmaceutical Regulations Committee



Chairman
Hirokazu Kurita,
Kracie Pharmaceutical, Ltd.

1. Matters relating to pharmaceutical affairs systems
2. Matters relating to surveys and research on the laws, regulations, and notifications associated with Kampo products and crude drug products

Technical Committee



Chairman
Yasuhiro Takasugi,
Tsumura & Co.

1. Matters relating to quality of pharmaceutical products and raw materials
2. Matters relating to listing on Japanese Pharmacopoeia and non-JP crude drug standards
3. Matters relating to impurities
4. Matters relating to GQP/GMP for pharmaceutical products
5. Matters relating to quality in international harmonization (PIC/S, FHH, ICH, and others)

Safety Committee



Chairman
Masanori Katori,
Tsumura & Co.

1. Prompt and thorough execution of safety measures such as revisions of the precautions standardized within JKMA
2. Securing of safety and promotion of proper use of Kampo products and crude drug products
3. Sharing and discussion of a variety of safety information (general situations and academic information)
4. Mutual training among members (lecture meetings and study meetings)
5. Cooperation and submission of opinions with administrative bodies and other organizations in the pharmaceutical industry
6. Responses to notifications on new points on statements in package inserts for ethical drugs
7. Appropriate responses to messages concerning reevaluation results of Kampo products for ethical use
8. Discussion on responses to consultation and complaints concerning Kampo products and others based on crude drugs

Code Committee

Code Review Board consists of 5 member companies participating in the Ethical Kampo Products Commission and the Crude Drugs Commission, in order to implement the Promotion Code for ethical Kampo formulation and crude drug.



Representative Member
Hiroyuki Matsuzuka,
Kracie Pharmaceutical, Ltd.

1. Matters relating to codes
 - (1) Familiarization with and promotion of Code of Practice
 - (2) Promotion of improvement in promotional activities under guidelines for sales information provision
2. Performance of matters relating to examination of outline of product information and others
 - (1) Examination of outline of product information and others and feedback on examination results
 - (2) Feedback on examination results to corporate members
 - (3) Revision of points to note in preparation for outline of product information and others, and familiarization among corporate members
 - (4) Reporting of opinions to and exchange of opinions with administrative bodies
3. Matters relating to Standard for Adequate Advertisement of Pharmaceutical Products

NHI Price Committee

The purpose of the NHI Pricing Committee is to contribute to the improvement of national medical care by ensuring the sustainable growth of ethical kampo formulations and crude drugs within systems such as medical insurance and the NHI drug price standard. The NHI Pricing Committee consists of 15 member companies.



Chairman
Makoto Sakaue,
Tsumura & Co.

1. Matters relating to survey/research, proposals, and countermeasures in connection with medical insurance systems and drug price standard systems
2. Matters relating to cooperation with FPMAJ medical insurance and drug price research council and information collection
3. Matters relating to holding of lecture meetings, study meetings, and others

Member Companies

Company	Address
Alps Pharmaceutical Ind. Co., Ltd.	2-10-50 Mukai-machi, Furukawa-cho, Hida-city, Gifu 509-4241
Amari Soice Co., Ltd.	13-295 Sinmachi, Husimi-ku, Kyoto 612-8081
Asgen Pharmaceutical Co., Ltd.	2008 Azakobora, Yamada-cho, Mizunami-shi, Gifu 509-6104
Co. Sugihara Tatuji Shoten	2-7-10 Kameido, Koto-ku, Tokyo 136-0071
Daiichi Sankyo Healthcare Co., Ltd.	3-14-10 Nihonbashi-cho, Chuo-ku, Tokyo 103-8234
Daiko Shoyaku Co., Ltd.	1-5-12 Shoken, Chikusa-ku, Nagoya 464-0084
Fukuda Shoten	477 Abeshinmachi, Sakurai-city, Nara 633-0054
Hino Pharmaceutical Co., Ltd.	2-3-15 Doshomachi, Chuo-ku, Osaka 541-0045
Honso Pharmaceutical Co., Ltd.	125 Furukawa-cho, Tenpaku-ku, Nagoya 468-0046
Ichigen Pharmaceutical Co., Ltd.	3-4-10 Kaname-cho, Toshima-ku, Tokyo 171-0043
Iskra Industry Co., Ltd.	1-14-2 Nihonbashi, Chuo-ku, Tokyo 103-0027
JPS Pharmaceutical Co., Ltd.	4-42-22 Higashiyamata, Tsuzuki-ku, Yokohama 224-0023
Kitanihon Pharmaceutical Co., Ltd.	55 Wakasugi, Kamiichimachi, Nakaniikawa-gun, Toyama 930-0314
Kobayashi Pharmaceutical Co., Ltd.	4-4-10 Doshomachi, Chou-ku, Osaka 541-0045
Konishi Pharmaceutical Co., Ltd.	2-33-11 Kamiishikiri-cho, Higashiosaka-city, Osaka 579-8012
Kotaro Pharmaceutical Co., Ltd.	2-5-23 Nakatsu, Kita-ku, Osaka 531-0071
Kowa Company. Ltd.	4-14 Nihonbashi-honcho 3chome, Chuo-ku, Tokyo 103-0023
Kracie Pharmaceutical Co., Ltd.	3-20-20 Kaigan, Minato-ku, Tokyo 108-8080
Kyushin Pharmaceutical Co., Ltd.	1-21-7 Wada, Suginami-ku, Tokyo 166-8533
Matsuura Yakugyo Co., Ltd.	24-21 Enjo-cho, Showa-ku, Nagoya 466-0054
Melsmon Pharmaceutical Co., Ltd.	2-35-6 Higashiryouke, Kawaguchi-city, Saitama 332-0003
Mikuni & Co., Ltd.	2-4-10 Doshomachi, Chuo-ku, Osaka 541-0045
Naganoken Materia Medica Co., Ltd.	879-2 Onbegawa, Sinonoi, Nagano-city, Nagano 388-8006
Naganoken Pharmaceutical Co., Ltd.	100-1 Outakimura, Kiso-gun, Nagano 397-0201
Nippon Funmatsu Yakuhin Co., Ltd.	2-5-11 Doshomachi, Chuo-ku, Osaka 541-0045
Nippon Shinyaku Co., Ltd.	14 Nishinoshomonguchi-cho, Kisshoin, Minami-ku, Kyoto 601-8550
Nitto Pharmaceutical Industries, Ltd.	35-3 Minamibiraki, Kamiueno-cho, Muko, Kyoto 617-0006
Ohki Pharmaceutical Co., Ltd.	3-3 Kandakaji-cho, Chiyoda-ku, Tokyo 101-0045
Ohkusa Pharmaceutical Co., Ltd.	1-17-15 Morisaki, Yokosuka, Kanagawa 238-0023

Member Companies

Company	Address
Ohsugi Pharmaceutical Co., Ltd.	1-1-2 Tennoji-cho, Minami, Abeno-ku, Osaka 545-0002
Ohta's Isan Co., Ltd.	2-3-2 Sengoku, Bunkyo-ku, Tokyo 112-0011
Ominedo Pharmaceutical Co., Ltd.	574 Nenarigaki, Yamatotakada-city, Nara 635-0051
Rohto Pharmaceutical Co., Ltd.	1-8-1 Tatsuminishi, Ikuno-ku, Osaka 544-8666
Ryukakusan Co., Ltd.	2-5-12 Higashikanda, Chiyoda-ku, Tokyo 101-0031
Sakamoto Kampow Pharmaceutical Inc.	1-5-12 Meishin-cho, Amagasaki-city, Hyogo 661-0021
Sampo Pharmaceutical Co., Ltd.	2-3-18 Shimoochiai, Shinjuku-ku, Tokyo 161-8541
Sankei Seiyaku Co., Ltd.	3-10-14 Ikegami Ota-ku, Toukyo 146-0082
Sanwa Shoyaku Co., Ltd.	6-1 Hiraide-Kogyo-Danchi, Utsunomiya-city, Tochigi 321-0905
Sato Pharmaceutical Co., Ltd.	1-5-27 Motoakasaka, Minato-ku, Tokyo 107-0051
Shinihonseiyaku Co., Ltd.	1-4-7 Otemon, Chuo-ku, Fukuoka 810-0074
Shinsei Pharmaceutical Industry Co., Ltd.	1269 Shimizutani, Takatori-cho, Takaichi-gun, Nara 635-0103
Taiko Pharmaceutical Co., Ltd.	3-34-14 Uchihonmachi, Suita-city, Osaka 564-0032
Taikoseido Pharmaceutical Co., Ltd.	2-1-27 Azuma-dori, Chuo-ku, Kobe 651-0076
Taisho Pharmaceutical Co., Ltd.	3-24-1 Takada, Toshima-ku, Tokyo 170-8633
Takeda Consumer Healthcare Company Limited.	1-8-2 Marunouchi, Chiyoda-ku, Tokyo 100-0005
TK Pharmaceutical Co., Ltd.	2-623-1 Horinouchi-cho, Ohmiya-ku, Saitama 330-0804
Tatebayashi Shokakudo Co., Ltd.	4-3-1 Higashiueno, Taito-ku, Tokyo 110-0015
Teikoku Kampo Seiyaku Co., Ltd.	636-1 Minato, Higashikagawa-city, Kagawa 769-2701
Tochimoto Tenkaido Co., Ltd.	3-21 Suehiro-cho, Kita-ku, Osaka 530-0053
Tohtohshu Seizo Co., Ltd.	6 Tenjin-cho, Shinjuku-ku, Tokyo 162-0826
Tokiwa Pharmaceutical Co., Ltd.	158 Kinoko, Sakura-shi, Chiba 285-0801
Toyo Yakuko Co., Ltd.	6-19-7 Hongo, Bunkyo-ku, Tokyo 113-0033
Tsumura & Co.	2-17-11 Akasaka, Minato-ku, Tokyo 107-8521
Uchida Wakanyaku Ltd.	4-3-3 Higashi-Nippori, Arakawa-ku, Tokyo 116-8571
Wakanyaku Medical Institute Ltd.	1-29-8 Shinjuku, Shinjuku-ku, Tokyo 160-0022
Wakunaga Pharmaceutical Co., Ltd.	4-5-36 Miyahara, Yodogawa-ku, Osaka 532-0003
Yamada Yakken Co., Ltd.	4-1-19 Hishiyaniishi, Higashiosaka-city, Osaka 577-0807
Yamamoto Kanpoh Seiyaku Co., Ltd.	156 Takihigashimachi, Komaki-city, Aichi 485-0035
Yatsume Seiyaku Co., Ltd.	2-14-14 Funabori, Edogawa-ku, Tokyo 134-0091
Yomeishu Seizo Co., Ltd.	16-25 Nanpeidai-cho, Shibuya-ku, Tokyo 150-8563
Zaiseido Pharmaceutical Co., Ltd.	8-31 Oda 2-chome, Wakayama-city Wakayama 640-8323
Zenyaku Kogyo Co., Ltd.	5-6-15 Otsuka, Bunkyo-ku, Tokyo 112-8650
Zeria Pharmaceutical Co., Ltd.	10-11 Nihonbashikobuna-cho, Chuo-ku, Tokyo 103-8351

* Alphabetical order of company name.




<https://www.nikkankyo.org/>

The map shows the surrounding area of the Japan Kampo Medicine Manufacturers Association (JKMA) building, located at 4F, Oceans Five. Key landmarks include Yushima Station on the Tokyo Metro Chiyoda Line (Exit 5), Suehirocho Station on the Tokyo Metro Ginza Line (Exit 4), Ochanomizu Campus of Nihon Pharmaceutical University, Tohto Bunkyo Hospital, and various streets like Kuramaebashi-dori Street and Chuo-dori Street. The JKMA building is highlighted in green.

The nearest stations
Four-minute walk from Exit 5 of Yushima Station on Tokyo Metro Chiyoda Line
Five-minute walk from Exit 4 (Exit 2) of Suehirocho Station on Tokyo Metro Ginza Line

Bakumondoto (cover photo)



4F Oceans Five, 3-7-7 Yushima, Bunkyo-ku,
Tokyo 113-0034
Telephone: 03-6284-2524 ; Fax: 03-6284-2534

Planned and edited by: JKMA PR Committee;
Prepared in July 2020